Clinical Trials List
2013-10-01 - 2017-12-31
Phase II
Terminated3
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/08/01
Investigators and Locations
Co-Principal Investigator
- Yi-Fang Tsai Division of General Surgery
- Ta-Chung Chao Division of Hematology & Oncology
- 賴亦貞 Division of Radiology
- 邱仁輝 Division of General Surgery
- 劉俊宇 Division of Hematology & Oncology
- 金光亮 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 張端瑩 Division of Hematology & Oncology
- SUNG-HSIN KUO Division of Hematology & Oncology
- 郭文宏 Division of General Surgery
- YEN-SHEN LU Division of Hematology & Oncology
- 林璟宏 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Chieh-Han Chuang Division of General Surgery
- Fang-Ming Chen Division of General Surgery
- Fu Ouyang Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
12 participants
-
Global
147 participants
